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Purpose: To describe the fabrication, evaluation, and preliminary in vivo safety of a
new drug delivery system (DDS) for topical anti–TNF-a antibody administration.
Methods: A DDS was fabricated using inverse template fabrication of a hydrophobic
three-dimensional porous scaffold (100–300 lm in diameter porosity) loaded with
10% polyvinyl alcohol hydrogel carrying 5 mg/ml (weight/volume) of anti–TNF-a
antibody. Drug-loaded DDS was sterilized with 25 kGy of gamma irradiation. Long-
term in vitro antibody affinity and release was evaluated at room temperature or 378C
using enzyme-linked immunosorbent assay (ELISA) and protein fluorescence. In vivo
clinical and histolopathological assessment was performed by subcutaneous
implantation in BALB/c mice for 3 months.
Results: Gamma irradiation, repeated dry/wet cycles, and storage at room
temperature for 1 year or 378C for 1 month had no deleterious effects on antibody
affinity. Anti–TNF-a release was high during the first minutes of aqueous exposure,
followed by stabilization and gradual, low-dose, antibody release over the next 30
days. Histopathologic evaluation of explanted DDS showed a fibrous pseudocapsule
and a myxoid acute/chronic inflammation without granuloma formation surrounding
the implants.
Conclusions: Sustained local delivery of anti–TNF-a antibody is feasible using the
described DDS, which provides stability of the enclosed antibody for up to 1 year of
storage. Preliminary results show good in vivo tolerance following subcutaneous
placement for 3 months. The proposed fabrication and sterilization process opens
new possibilities for the delivery of biologic agents to the anterior surface of the eye.
Translational Relevance: The described DDS will facilitate the treatment of ocular
surface diseases amenable to biologic therapy.
Introduction
Biologic agents targeting key cytokines and growth
factors are being applied to an expanding spectrum of
human systemic diseases and ocular disorders. For
example, intravitreal injection of anti–vascular endo-
thelial growth factor (VEGF) agents has become the
gold standard of treatment of choroidal neovascular-
ization and diabetic macular edema.1–4 Applications
of anti-VEGF therapy are also currently being
investigated for several ocular surface conditions
including corneal neovascularization,5 pterygium,6
and high-risk penetrating keratoplasty.7
Likewise, monoclonal antibody against tumor
necrosis factor alpha (TNF-a), such as infliximab
(Janssen Biotech, Inc., Horsham, PA), is an interest-
ing therapeutic approach to the targeted treatment of
ocular surface diseases. Indeed, TNF-a is a pleotropic
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cytokine with important contributions in the patho-
genesis of inflammation, angiogenesis, and collage-
nolysis.8–10 Systemic administration of infliximab has
been reported to stabilize corneal melting in patients
with autoimmune diseases (rheumatoid arthritis,
Crohn disease, peripheral ulcerative keratitis) that
were recalcitrant to other treatment modalities.11–14
Intravenous infliximab has also improved the reten-
tion of the Boston Keratoprosthesis, an artificial
cornea, in patients with Stevens-Johnson syndrome or
rheumatoid arthritis and recurrent corneal melt.15–17
Further, a single intraperitoneal dose of 6.25 mg/kg of
anti–TNF-a in mice inflicted with alkali corneal burns
significantly reduced corneal inflammation, neovas-
cularization, and inhibited retinal ganglion cell layer
apoptosis as compared with isotype IgG treatment
control.18
A limitation to the use of biologic therapies is the
risk of significant systemic adverse events. Local
administration achieves lower systemic exposure to
the drug and therefore is likely associated with lower
rates of severe adverse events. The use of infliximab
eye drops has been investigated as an alternative
modality for local drug delivery. The administration
of topical infliximab eye drops reduced corneal
opacity, perforation, and eyelid fibrosis in a mouse
model of corneal alkali burn,19 and improved tear
volume, corneal surface regularity, and goblet cell
density in a mouse model of dry eye.20 In rabbit
models, the use of topical infliximab prevented
corneal neovascularization21 and suppressed subcon-
junctival wound healing after trabeculectomy.22 On
the other hand, cerebrovascular accidents are recog-
nized complications of systemic anti-VEGF therapy23
while anti–TNF-a agents are associated with a risk of
opportunistic infections, malignancies, infusion reac-
tions, as well as cardiac and renal toxicity.24,25 Local
administration achieves lower systemic exposure to
the drug, and therefore is likely associated with lower
rates of severe adverse events. For example, the risk of
arterial thromboembolic events is approximately 3%
with intravitreal bevacizumab administration but
increases to 10% with intravenous use.26,27 The
sustained and selective release of biologics to diseased
tissue using drug-eluting carriers is a promising
therapeutic alternative for maximizing bioavailability
while minimizing side effects. However, the direct
delivery of biologic agents to the front of the eye is
challenging. The large molecular size (~150 kD) and
the hydrophilic nature of antibodies limit corneal
epithelial penetration, and thus, limit the bioavail-
ability to the corneal stroma and the rest of the
anterior segment. The use of a drug-eluting polymer
placed on the ocular surface prolongs the precorneal
residence time of the medication, and is thus one
approach to improve antibody penetration when
compared with eye drops.28 This effect is even more
important for ocular diseases that cause epithelial
barrier loss. Further, product sterilization is an
outstanding challenge in the manufacture and in vivo
application of biologic drug-eluting polymers. Heat or
gas sterilization processes may damage protein
structure and alter the antibody’s antigen binding
affinity or modify the systemic response to the
biologic agent, thereby limiting the manufacturing
options and increasing the cost of biologic drug-
eluting polymers.29,30
The purpose of this study was to develop an anti–
TNF-a drug delivery system (DDS) and to test
gamma irradiation as an alternative method of post
manufacturing sterilization. Moreover, drug stability
and release were examined in vitro while in vivo
adverse effects were evaluated histopathologically
following subcutaneous implantation in mice.
Materials and Methods
Preparation of the DDS
A three-dimensional (3D) porous polydimethylsi-
loxane (PDMS) block was prepared as previously
described.31 Water dissolvable particles with a diam-
eter between 100 and 300 lm were used to create the
negative PDMS template. The particles were dis-
solved by agitation in 958C water for 3 hours resulting
to an interconnected porous PDMS network (Fig. 1),
as determined by nondestructive 3D x-ray micro-
computed-tomography (X-Tek HMXST225; Nikon
Metrology Inc., Brighton, MI), and 3D image
reconstruction (VGStudio Max 2.2; Volume Graph-
ics, Heidelberg, Germany; Fig. 1). The sponge-like
microporous PDMS provided 50% cavitation volume
and was sectioned into small segments of 5 mg (~53
23 1 mm).
Polyvinyl alcohol (PVA) 10% wt/vol loading
polymer was prepared as follows: PVA powder (#
363,146-500G; Sigma Aldrich, St. Louis, MO) was
slowly added into deionized (DI) water and stirred on
a hotplate, heating up to 908C to 988C until the PVA
powder was totally dissolved. The mixture was cooled
to room temperature (RT) and infliximab lyophilized
powder (a chimeric monoclonal an anti–TNF-a
antibody) was suspended at a 34:1 wt/vol ratio
(infliximab:PVA solution) resulting in an anti–TNF-
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a antibody concentration of 5 mg/ml. The polymer
was then loaded into the 3D microporous PDMS
using a vacuum chamber and air-dried (Fig. 2).
The infliximab-loaded PDMS DDS was stored at
room temperature until use. Gamma irradiation was
applied to select DDSs used in the drug release assays
and to all DDSs used in the in vivo assays given the
need for sterilization of the device. A Cobalt-60
source was used to deliver a total dose of 25 kGy,
which is the standard requirement for tissue steriliza-
tion.
Anti–TNF-a Stability and Release From the
Drug Delivery Device
The stability and release of infliximab were
evaluated using a commercially available sandwich
enzyme-linked immunoassay (ELISA; Quantikine
Human TNF-a Immunoassay; R&D Systems, Min-
neapolis, MN). The assay protocol was modified to
include a 1-hour incubation at 378C to allow antigen-
antibody binding between a known quantity of TNF-
a (125 pg/mL) and the infliximab eluted from the
DDS TNF-a bound by infliximab through antibody-
antigen interaction is unable to bind to the capture
antibody coating of the ELISA well and is, therefore,
washed away during the subsequent steps of the
assay. The remaining TNF-a in the solution, which
was not bound by anti–TNF-a antibody, is then
measured using the standard steps of the assay.32,33
The amount of TNF-a bound by infliximab is then
calculated by subtraction from the initial amount of
Figure 1. X-ray microtomography of the porous PDMS. (A)
Macroscopic and (B) microscopic appearance of porous PDMS.
The microstructure of PDMS was determined using nondestructive,
molybdenum-generated radial x-ray scans. Three-dimensional
image reconstruction of the microcomputed-tomography (lCT)
was achieved using VGStudio Max 2.2 image reconstruction
software. The porous cavities are subsequently loaded with
infliximab using polyvinyl alcohol as a loading polymer.
Figure 2. Manufacturing sequence of the anti–TNF-a drug delivery system (DDS).
3 TVST j 2016 j Vol. 5 j No. 2 j Article 11
Robert et al.
TNF-a loaded into each well. Anti–TNF-a antibody
activity was quantified as the percentage of captured
TNF-a (percent TNF-a inhibition): [125 pg/mL
minus TNF-a concentration measured by ELISA]
divided by 125 pg/mL). A standard curve was
prepared with each assay using TNF-a concentrations
between 0 and 125 pg/mL. The percentage of TNF-a
inhibition was compared with inhibition values for
known infliximab concentrations varying between 0
and 5000 ng/mL. The relationship between infliximab
concentration and TNF-a binding to the ELISA was
modeled with the following standard curve (allometric
equation): infliximab concentration (y) ¼ 0.05426 3
(optical density)4.51279, R2 ¼ 0.99. The infliximab
standard curve remained within the validated detec-
tion range of TNF-a (15.6  1000 pg/mL) for the
ELISA. All measurements were performed in tripli-
cate.
The stability of the anti–TNF-a antibody was
assessed under different conditions. First, the anti–
TNF-a/PVA loading polymer mixture was evaluated
after dry storage for 1 week at 48C and 378C. On the
day of the assay, the anti–TNF-a/PVA loading
polymer was diluted in normal saline to an infliximab
concentration of 4 lg/mL, mixed 50:50 with 250 pg/
mL TNF-a (effective concentration of 125 pg/mL of
TNF-a) and incubated for 1 hour at 378C. The
percentage of TNF-a inhibition using ELISA was
calculated as described above. Also, the DDS was
evaluated after dry storage at room temperature (RT)
or 378C for up to 4 weeks. The DDS was submerged
and incubated in 400 lL of 125 pg/mL TNF-a for 1
hour at 378C and the soaking solution was used for
the subsequent ELISA. Fresh infliximab solution (4
lg/mL, lyophilized powder dissolved in normal
saline) was prepared as a positive control.
Sham PVA and sham DDS (without infliximab)
were used as controls to ensure that the polymers did
not adsorb or neutralize significant amounts of TNF-
a. Sham PVA (PVA 10% without infliximab) was
prepared and stored at 48C for 1 week (Fig. 3A).
Sham PVA was diluted in normal saline using the
same dilution factor used for anti–TNF-a/PVA. The
diluted sham PVA was mixed with TNF-a, incubated
for 1 hour at 378C and used for the subsequent
ELISA. Sham DDS were prepared, sectioned into 5-
mg segments and stored at RT for 4 weeks prior to
being assayed. Using an identical technique to
infliximab loaded DDS, sham DSS segments were
submerged and incubated in 400 lL of 125 pg/mL
TNF-a solution for 1 hour at 378C. The soaking
solution was used for the subsequent ELISA.
Three segments of the DDS were used to assess
drug release and stability after serial assays and wet-
dry cycles over a 4-week period. After 1 or 2 weeks of
dry storage at RT or 378C, the segments were
incubated with 125 pg/mL TNF-a at 378C for an
hour. The soaking solution was used for the ELISA
assay while the DDS segments were recovered, air-
dried, and stored at RT until a repeat assay was
performed assay.
To assess the drug-eluting properties of the DDS,
5-mg segments of the polymer were sequentially
soaked in either 500 lL or 1000 lL of 0.9 % normal
saline and incubated at 378C for a 10-day period. The
volume of soaking solution did not significantly alter
the release of infliximab (Supplemental Fig. S1).
Wherein infliximab is known to completely dissolve at
a concentration of 10 mg/mL,10 the expected amount
of infliximab present in the DDS would only achieve
concentrations in the lg/mL scale. Thus, the 500 and
1000 lL volume achieves sink conditions.
Figure 3. Stability of anti–TNF-a antibody in the drug delivery system. (A) Infliximab in polyvinyl alcohol (4 lg/mL) following 1 week at
48C or 378C has similar TNF-a binding affinity and inhibition when compared with freshly prepared 4 lg/mL infliximab. TNF-a inhibition
with and without blank PVA or PDMS is negligible, demonstrating that neither polymer adsorbs TNF-a nor interfere with the assay. (B)
Infliximab in PDMS is stable after 1 week at RT as well as 1 and 4 weeks at 378C. (C) Stability of anti–TNF-a loaded PDMS after 4 weeks at
RT or 378C following repeated cycles of incubations in 125 pg/mL TNF-a solution and air-drying (†one cycle, †† two cycles).
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Nongamma- and gamma-irradiated DDS segments
were each sequentially transferred to fresh soaking
solution (500 lL) at predetermined time-points over a
1-month period. These included 3 and 24 hours as
well as 2, 4, 6, 8, 10, 12, 15, 17, 20, 22, 25, 28, and 31
days after preparation. The different soaking solu-
tions were stored at 48C until the day of the assay.
Each soaking solution, which contained infliximab
released from the DDS, was allowed to react with
equal volume of 250 pg/mL TNF-a (final TNF-a
concentration of 125 mg/mL) for 1 hour at 378C prior
to proceeding with the ELISA using the standard
protocol. This drug-elution experiment was repeated
using nongamma- and gamma-irradiated DDS that
had previously been stored at RT for 1 year.
Given the limitations in quantifying the early
release of high concentrations of infliximab using
ELISA, quantification of infliximab protein eluted
from the DDS was also performed using fluorescence
spectroscopy with measurement of the infliximab
fluorescence signal at 340 nm, using an excitation
wavelength of 280 nm. First, the real-time elution
characteristics were evaluated using constant moni-
toring of fluorescence measurements over 2 hours of a
freshly prepared DDS placed inside a 13 1 cm quartz
cuvette containing 1.5 mL of 0.9% normal saline with
constant agitation using a magnetic stirrer. The long-
term release of infliximab was assessed by soaking the
DDS in 1000 lL of normal saline at RT without
stirring. Sequentially, the DDS was transferred to
fresh normal saline over a 35-day period (at days 1, 3,
7, 14, 23, and 35). Fluorescence spectroscopy was
performed on each of the soaking solutions and the
amount of released infliximab was calculated as
micrograms of anti–TNF-a antibody per day of
soaking.
In Vivo Tolerance of the Drug Delivery
Device
In vivo studies were approved by the Animal Care
Committee of the Massachusetts Eye and Ear
Infirmary. All animal-based procedures were per-
formed in accordance with the ARVO Statement for
the use of Animals in Ophthalmic and Vision
Research, and the National Institutes of Health
Guidance for the Care and Use of Laboratory
Animals.
All procedures were performed under general
anesthesia using intraperitoneal ketamine (120 mg/
kg; Putney Inc., Portland, ME) and xylazine (20 mg/
kg; Vedco Inc., St. Joseph, MO) as previously
described.18 Postoperative analgesia was provided
using subcutaneous buprenorphine hydrochloride
(0.05 mg/kg, Buprenex Injectable; Reckitt Benckiser
Healthcare, Ltd., Slough, UK).
In order to preliminarily assess the in vivo safety,
sections of the gamma-irradiated DDS were surgically
implanted in the subcutaneous space of the dorsal fat
pad in two BALB/c male mice and kept in situ for 3
months. Sham DDS without anti–TNF-a antibody
was implanted in two separate BALB/c male mice as
polymer controls. At 3 months, the DDS were
explanted for further clinical and histopathologic
analysis. The DDS and surrounding tissue was
sectioned and stained with hematoxylin-eosin and
Masson trichrome.
Statistical Analysis
Statistical analysis was performed using GraphPad
Prism software (San Diego, CA). The inhibition of
TNF-a by released infliximab was compared between
time point and storage conditions using the nonpara-
metric Kruskal-Wallis (KW) test. Dunn’s multiple
comparisons test was performed for each pair of the
testing conditions if the P value was below 0.05. Per
convention, a two-tailed P value below 0.05 was
defined as being statistically significant. Bonferroni
correction was applied as appropriate.
Results
Stability Evaluation of Drug Delivery Device
Quantification of infliximab, performed using a
validated ELISA assay,32 revealed stable binding to
TNF-a following storage in various conditions.
Infliximab-PVA (4 lg/mL) stored for 1 week at either
48C or 378C had similar TNF-a inhibition when
compared to freshly prepared infliximab (4 lg/mL)
with TNF-a inhibition of 79.4% 6 0.2%, 78.7% 6
1.3%, and 77.4%6 0.1%, respectively (P¼ 0.286; KW
test). PVA without infliximab did not show any
inhibition of TNF-a (0.0% 6 2.9%; Fig. 3A).
The 5-mg DDS segments stored at RT or 378C for
1 week inhibited 71% 6 3% and 70% 6 3% of the
TNF-a, respectively. The level of TNF-a inhibition
after 4 weeks at 378C was not significantly changed
(80.5% 6 3%, P ¼ 0.181; KW test). Further, sham
DDS (without anti–TNF-a) did not lead to significant
inhibition of TNF-a (3.0% 6 1.9%; Fig. 3B). DDS,
stored at RT and/or 378C for 4 weeks, continued to
show 63% to 68% inhibition of TNF-a despite
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previous repeated dry–wet cycles and incubation with
TNF-a solution (P¼ 0.104; KW test; Fig. 3C).
Anti–TNF-a Release from Drug Delivery
Device
As shown in Figure 4, the release of biologically
active anti–TNF-a antibody from the DDS in the first
3 hours of soaking was significant. TNF-a inhibition
was almost complete (96.9% 6 0.8%) and exceeded
the lower detection limit of the assay. At 24 hours,
release of infliximab remained high with 82.8% 6
9.8% inhibition of TNF-a, corresponding to an
infliximab release of 2.11 lg/day. Lower levels of
drug release occurred at zero order kinetics for the
following 30 days. During this period (days 2–31),
average TNF-a inhibition was 24% 6 6% and
corresponded to infliximab release of 1.23 6 0.29
ng/day (Fig. 4). Gamma-irradiated DDS had similar
infliximab release and TNF-a inhibition characteris-
tics when compared with nongamma-irradiated DDS
(Fig. 4B). Further, nongamma- and gamma-irradiat-
ed DDS that had been kept at RT for 1 year showed a
retained ability to release biologically active inflix-
imab (Fig. 4C). The release curve showed high levels
(.80%) of TNF-a inhibition for the first 4 and 12
days of continuous aqueous exposure for the non-
gamma- and gamma-irradiated DDS, respectively. In
contrast, freshly prepared DDS only exhibited this
level of TNF-a inhibition over the first 24 hours.
Using an excitation wavelength of 280 nm, the
fluorescence signal of freshly prepared infliximab in
normal saline at 340 nm was linearly correlated to
infliximab concentrations between 0 to 36.3 lg/mL
(R2 ¼ 0.999; Fig. 5A). Real-time monitoring of
infliximab release from DDS of 5 mg total weight
revealed that the burst release occurred within the
first 30 minutes of soaking and that slow elution
continued thereafter (Fig. 5B). A total of 44.9 lg of
infliximab was released over the 2-hour assay. The 35-
day infliximab release curve reveals significant early
antibody release (27.2 lg/day over first 24 hours),
stabilization of the release kinetics between days 7 and
14, followed thereafter by zero-order release (23 6 6
ng/day between days 14 and 35; Fig. 5C).
In Vivo Tolerance of the Drug Delivery
Device
A DDS (5 3 2 3 1 mm in size) was implanted
subcutaneously beneath the dorsal fat pad in two
anesthetized BALB/c mice without complication. The
mice were observed for 3 months and did not show
evidence of clinical inflammation, infection, skin
necrosis, or systemic illness. After 3 months, the
explanted DDS with and without anti–TNF-a anti-
body showed similar histopathological findings (Fig.
6). The implants were found to have been inserted
either in a premuscular plane or underneath multiple
layers of striated muscle cells. A thin and irregular
translucent lamina of DDS residue was adherent to
the tissue edges, but most of the device had been
dislodged or dissolved during tissue processing.
Fibroblastic proliferation was detected in the host
tissues immediately surrounding the implants and
Figure 4. Anti–TNF-a antibody release after continuous aqueous
exposure of the drug delivery system. (A) The release of
biologically active anti–TNF-a antibody from the drug delivery
system (DDS) over 31 days is quantified as the relative inhibition of
TNF-a (125 pg/mL). Due to burst release of anti–TNF-a antibody,
TNF-a inhibition was almost complete after the initial 3-hour
soaking period. High levels of anti–TNF-a antibody were released
in the next 24 hours, followed by lower but stable zero-order
release for the subsequent 30 days. (B) Gamma irradiation with 25
kGy did not impede the release characteristics or the anti–TNF-a
antibody or the binding affinity when compared with nongamma-
irradiated DDS. (C) After 1 year of shelf storage, nongamma- as well
as gamma-irradiated DDS showed preserved inhibition of TNF-a.
The release curve shows prolongation of the initial burst release of
anti–TNF-a antibody, which is particularly marked for the gamma-
irradiated DDS.
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manifested little evidence of collagen synthesis as
revealed by the Masson trichrome stain which
demonstrated the absence of blue stain interstitial
fibrillar material (Fig. 6A). The fibroblastic pseudo-
capsule was most compact at the superficial edge and
looser at the base and lateral edges of the implant.
The spindle cells responsible for the pseudocapsule
appeared to be myofibroblasts in view of their
cytoplasmic fuchsinophilia with the Masson tri-
chrome stain. A mixed mononuclear and polymor-
phonuclear leukocytic inflammatory response was
Figure 5. Release of anti–TNF-a antibody from the drug delivery
system using fluorescence spectroscopy. Fluorescence calibration
curve for anti–TNF-a antibody in normal saline buffer (excitation
wavelength of 280 nm, monitoring wavelength [k] of 340 nm). The
fluorescence signal linearly correlates to concentrations of freshly
prepared anti–TNF-a antibody between 0 and 80 lg/mL (R2 .
0.99). (B) Real-time quantification of released anti–TNF-a antibody
from a 5 mg total weight DDS placed into 1.5 mL of normal saline
at room temperature as measured by fluorescence. (C)
Fluorescence quantification of anti–TNF-a antibody released from
5 mg total weight DDS placed into 0.5 mL of normal saline at room
temperature over 35 days.
Figure 6. Histopathologic findings of implanted with anti–TNF-a
antibody (A–C) DDS and sham DDS (D–F). (A) Masson trichrome
stain discloses that the collagen of the dermis is blue. The
subdermal fat bearing cross sections of hairs is uninflamed. Note
the pseudocapsule lining the implant cavity (ca) below is lightly
red staining and lacks blue staining collagen as well as prominent
capillaries. (B) Upon the inside surface of the pseudocapsule
below rests an exudative inflammatory process with suspended
acute and chronic inflammatory cells. Similar cells are also
present in the more compact fibroblastic pseudocapsule devoid
of capillaries. DDS cavity (ca). (C) Cavity of an explanted DDS (ca)
that contained anti–TNF-a antibody. The implant encroaches on
the subcutaneous fat with hairs and was located above the
striated muscle. An inflammatory exudate with suspended cells is
apparent multifocally, especially on the inside of the fibroblastic
pseduocapsule at the lateral and vertically oriented edges. There
is considerable myxoid change in the fat on the left adjacent to
the cavity. Striated muscle is revealed as an uninflamed
eosinophilic band below the cavity. (D) More compact zone of
cavity wall beneath striated muscle fibers below. (E) Bland
stromal cells and scattered mononuclear inflammatory cells
constitute the wall delimiting the cystic cavity below. Several
small capillaries can be seen in the wall. DDS cavity (ca). (F) Low
power photomicrograph of cavity (ca) that had a DDS without
anti–TNF-a antibody. The epidermis and dermis are present on
the top, beneath which is a layer of uninflamed fat. The implant is
located beneath the subcutaneous musculature. ([A–D, F]
hematoxylin and eosin, 350, 3200, 3200, 350, 3200; [E] Masson
trichrome,3100).
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observed in multiple foci along the inner aspect of the
fibrous pseudocapsule (Fig. 6B). The implants with
anti–TNF-a antibody (Fig. 6A–C) showed somewhat
greater inflammation immediately abutting the DDS
The implants without anti–TNF-a antibody (Fig. 6D–
F) had a slightly greater presence of capillaries in the
vicinity of the implant. In one of these infliximab-
loaded implants, a focus of myxoid reaction contain-
ing acute and chronic inflammation was seen in the
adjacent fat. Granulomatous zones were not observed
around or near the implants.
Discussion
We describe the preparation of a novel DDS made
of PDMS/PVA for topical delivery of anti–TNF-a
antibodies and demonstrate its biological stability,
drug-release characteristics, and in vivo tolerability.
Further, we establish that post production exposure
of the DDS to gamma irradiation may be a feasible
sterilization option without undue consequences to
the antibody’s affinity and biological activity.
Local administration of anti–TNF-a requires
lower doses than systemic administration, thus
minimizing costs and the risk of systemic complica-
tions. For the cornea, the short drug residence time
achieved with eye drops due to normal tear flow and
reflex tearing are important barriers to achieving
sufficient drug concentrations in the target tissue.
This is especially true with larger hydrophilic mole-
cules such as biologic agents. Subconjunctival admin-
istration is able to achieve greater bioavailability but
involves an invasive procedure.34 Other systems have
been developed for sustained drug delivery to the
ocular surface. For example, colloidal formulations
such as liposomes and nanoparticles can be designed
to improve corneal penetration and drug stability.35
While improving bioavailability, these thicker formu-
lations may cause visual blurring by adhering on the
corneal surface upon instillation, which in turn, may
harm patient compliance. Contact lenses have also
been used for the release of several therapeutic agents
including antibiotics and glaucoma drugs.36,37 How-
ever, the needs of optical clarity, oxygen permeability,
and the specific design for fit over the cornea, limit the
types of materials and the degree of customization
that is otherwise possible with other drug delivery
systems.38 Dissolvable inserts share a similar ap-
proach to the current DDS by prolonging drug
residence time on the ocular surface. Drug release
and dissolution of these inserts are dependent on
hydration and tear flow, which may be highly variable
in patients with inflammatory conditions that would
necessitate anti–TNF-a therapy.39 Ocusert, a non-
dissolvable lower-lid insert, can be used to deliver
pilcarpine medication to the eye. A membrane barrier
is used to control the release, which may not be
suitable for larger biologic agents.40
The delivery of therapeutic proteins, such as anti–
TNF-a antibody poses additional challenges includ-
ing those of drug instability, immunogenicity, and
shorter half-lives in the body.30 Various techniques
have been employed to stabilize protein, mainly by
encapsulating the protein in biodegradable poly-
mers.30 Hydrogels and porous polymeric scaffolds
are the two main delivery systems used to provide
controlled and sustained protein delivery for longer
periods of time. PVA hydrogel is a nontoxic and
noncarcinogenic biocompatible hydrophilic polymer
suitable for mixing at low temperatures, thus pre-
venting protein denaturation. Further, PVA allows
water diffusion at a relatively slow rate causing
expansion of the hydrogel and change in release
characteristics.41 However, the PVA structure is less
resilient to deformation at increased mechanical
stresses, such as occurs during blinking.42 On the
other hand, polymeric scaffolds can be tailored to
deliver drugs for longer durations. However, their
manufacturing often involves chemicals and tech-
niques that can cause protein denaturation. PDMS is
a popular biocompatible siloxane polymer used for
drug delivery. Prepolymer (liquid form) PDMS is
often mixed with the drug prior to the curing process.
The two important limitations of this system are the
use of peroxide or heat to cure the prepolymer and the
inability of polar drugs (hydrophilic proteins) to mix
well in nonpolar (hydrophobic) PDMS. Therefore,
PDMS is preferentially used as drug delivery system
of nonbiologic, nonpolar drugs.43 However, cured
PDMS holds several advantages. It is mechanically
very stable, nondegradable, and biocompatible.
PDMS can be used to fabricate polymer scaffolds,
suitable for use in tissues that exhibit high mechanical
stresses, such as the lid and ocular surface. Its low
surface energy (hydrophobicity) prevents wetting by
polar liquids. The addition of surface roughness by
the porous structure enhances its hydrophobicity.31
Hydrophobicity slows penetration of water into the
PDMS porous network, thereby preventing rapid
hydration and release of the loaded drug.
In the current study, a combination of nonbiode-
gradable porous PDMS scaffold, loaded with PVA
hydrogel that contained anti–TNF-a antibody was
used. The preparation of porous PDMS was per-
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formed using biocompatible sacrificial particles, as
previously described.31 The loading technique of anti–
TNF-a antibody into PVA was benign and aimed at
reducing the risk of protein denaturation. Similarly,
PVA loading into the PDMS porous network was
performed at low temperatures with negative pres-
sure. Loaded protein was not exposed to cross-
linkers, chemicals, or heat during the process.
Functional experiments of anti–TNF-a mixed with
PVA showed antibody functional stability. In our
system, PVA swelling was restricted by the porous
PDMS scaffold and water diffusion was further
reduced by the low surface energy of PDMS.
Our experiments demonstrate that infliximab can
be successfully loaded into a carrier polymer and
remains biologically stable when kept at 378C for up
to 1 month. In addition, exposure of the infliximab-
PVA-PDMS design to high dose (25 KGy) gamma
irradiation was not deleterious to the protein binding
affinity, paving the possibility for convenient post
manufacturing sterilization. This is particularly im-
portant given the historical burden of biologic drug
production, requiring pathogen-free production of
antibodies to avoid later antibody denaturation
during the sterilization process.44 Our results using
DDS after 1 year of RT shelf storage indicate that the
release of biologically active antibody is possible.
However, further process optimization of DDS
fabrication, storage, and handling is necessary to
reduce the variability of infliximab release. This is
particularly true for gamma-irradiated DDS.
The release curves obtained through fluorescence
spectroscopy and ELISA correlate well with each
other, as both quantification methods show a rapid
burst of anti–TNF-a antibody released from the DDS
which is then followed by slow yet stable release after
1 to 2 weeks. However, as fluorescence measurements
are based on native tryptophan fluorescence and not
biologically active antibody, this technique overesti-
mates the amount of infliximab released from the
DDS when compared with ELISA measurements.
The burst of infliximab release is thought to be related
to the infliximab/PVA found on the surface of the
polymer and can be expected to be higher in an
agitated solution. The subsequent slower release rates
likely relate to the diffusion of infliximab from inside
the PDMS polymer. While the amount of released
infliximab appears low, it is important to note that
TNF-a is a potent cytokine. It has been shown that a
minute quantity of 10 ng/mL of recombinant TNF-a
can induce appoptosis.45 Conversely, a small amount
of locally delivered TNF-a inhibitor can potentially
have biologically relevant and meaningful protective
effect on the ocular surface. Preliminary in vivo data
have shown detectable levels of infliximab in the DDS
after 3 months of subconjunctival implantation in
rabbit eyes. Detection of infliximab was performed
using monoclonal anti-IgG antibody in tissue sections
of the explanted DDS Explanted sham DDSs showed
lack of anti-IgG staining (Zhou C, et al. IOVS. 2016;
ARVO E-Abstract 1271).
Finally, the DDS failed to show any sign of local or
systemic toxicity when implanted subcutaneously for
up to 3 months in mice. A mixed-acute and chronic
inflammatory cell reaction was noted within the
compact fibroblastic pseudocapsule as well as in areas
with a more myxoid matrix, particularly in the implant
with the chimeric antibody. This may represent a
reaction to the chimeric antibody’s antigenicity.
However, the formation of a fibrous capsule around
biomaterial implants is a common phenomenon, and
thus, it is not solely due to the antigenicity of anti–
TNF-a.46 Alternatively, the inflammation may be a
consequence of the differential trauma of surgical
implantation of the DDS There were slightly fewer
capillaries in the DDS specimen containing anti–TNF-
a antibody. This is not surprising as infliximab has
been shown to reduce angiogenesis in the corneal
stroma.4,16 No granulomatous elements were detected
near the implants. The implants therefore appeared to
be satisfactorily tolerated in vivo. With the passage of
time the inflammatory response would have been
expected to subside, leaving behind only a quiescent
contracted pseudocapsular scar with the progressive
deposition of collagen.
The long-term objective is to place the DDS in the
conjunctival fornix to circumvent the short precorneal
residence time seen with eye drops. It is likely to be
well-tolerated while allowing a more targeted and
specific approach to ocular surface drug delivery. This
would allow the elution of high doses of antibody
initially followed by zero-order release for the
subsequent month. Further, the use of a carrier
polymer might be more attractive to clinicians and
patients given its expected ease of insertion and
removal into the conjunctival fornix, allowing for
titration of therapy as medically necessary and
ensuring patient adherence. Alternatively, the DDS
could be placed in the subconjunctival space. While
this would likely provide better diffusion dynamics
and saturation in the eye, this approach is more
invasive as it would require the surgical implantation
and removal of the polymer when depleted of anti–
TNF-a antibody. Our future studies will target to
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generate monodisperse porosity at different pore
sizes. We expect that this will influence the diffusion
dynamics of biologic agents from the DDS.
Conclusion
In conclusion, anti–TNF-a DDS made of PDMS/
PVA polymers can be prepared and sterilized using
gamma irradiation, providing an initial burst of
biologically active antibody followed by zero-order
release of low amounts of antibody for up to 1 month
in vitro. The demonstrated long-term biological
stability as well as in vivo tolerability of anti–TNF-a
carrier polymer may facilitate future investigations
targeting TNF-a as a modulator of various ocular
surface diseases and may open the possibility of topical
delivery of multiple biologic agents simultaneously.
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